A meta-analysis of cognitive impairment and decline associated with adjuvant chemotherapy in women with breast cancer

Ono, Miyuki, Ogilvie, James M., Wilson, Jennifer S., Green, Heather J., Chambers, Suzanne K., Ownsworth, Tamara and Shum, David H. K (2015) A meta-analysis of cognitive impairment and decline associated with adjuvant chemotherapy in women with breast cancer. Frontiers in Oncology, 5 59.1-59.19. doi:10.3389/fonc.2015.00059


Author Ono, Miyuki
Ogilvie, James M.
Wilson, Jennifer S.
Green, Heather J.
Chambers, Suzanne K.
Ownsworth, Tamara
Shum, David H. K
Title A meta-analysis of cognitive impairment and decline associated with adjuvant chemotherapy in women with breast cancer
Journal name Frontiers in Oncology   Check publisher's open access policy
ISSN 2234-943X
Publication date 2015-03-10
Sub-type Article (original research)
DOI 10.3389/fonc.2015.00059
Open Access Status DOI
Volume 5
Start page 59.1
End page 59.19
Total pages 19
Place of publication Lausanne, Switzerland
Publisher Frontiers Research Foundation
Collection year 2016
Language eng
Formatted abstract
A meta-analysis was performed to quantify the magnitude and nature of the association between adjuvant chemotherapy and performance on a range of cognitive domains among breast cancer patients. A total of 27 studies (14 cross-sectional, 8 both cross-sectional and prospective, and 5 prospective) were included in the analyses, involving 1562 breast cancer patients who had undergone adjuvant chemotherapy and 2799 controls that included breast cancer patients who did not receive adjuvant chemotherapy. A total of 737 effect sizes (Cohen’s d) were calculated for cross-sectional and prospective longitudinal studies separately and classified into eight cognitive domains. The mean effect sizes varied across cross-sectional and prospective longitudinal studies (ranging from −1.12 to 0.62 and −0.29 to 1.12, respectively). Each cognitive domain produced small effect sizes for cross-sectional and prospective longitudinal studies (ranging from −0.25 to 0.41). Results from cross-sectional studies indicated a significant association between adjuvant chemotherapy and cognitive impairment that held across studies with varied methodological approaches. For prospective studies, results generally indicated that cognitive functioning improved over time after receiving adjuvant chemotherapy. Greater cognitive impairment was reported in cross-sectional studies comparing chemotherapy groups with healthy control groups. Results suggested that cognitive impairment is present among breast cancer patients irrespective of a history of chemotherapy. Prospective longitudinal research is warranted to examine the degree and persisting nature of cognitive impairment present both before and after chemotherapy, with comparisons made to participants’ cognitive function prior to diagnosis. Accurate understanding of the effects of chemotherapy is essential to enable informed decisions regarding treatment and to improve quality of life among breast cancer patients.
Keyword Adjuvant chemotherapy
Breast cancer
Cognitive functioning
Meta-analysis
Moderators
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: UQ Centre for Clinical Research Publications
Non HERDC
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 14 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 14 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 08 Mar 2016, 11:56:56 EST by Matthew Lamb on behalf of School of Medicine